Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
Holding BHVN?
Track your performance easily
BHVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.97 - $62.21
Previous Close$52.96
Volume870.49K
Average Volume (3M)1.00M
Market Cap
$5.35B
Enterprise Value$4.94B
Total Cash (Recent Filing)$436.95M
Total Debt (Recent Filing)$26.19M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 06, 2024EPS Estimate
-$1.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.15
Shares Outstanding94,542,253
10 Day Avg. Volume1,116,641
30 Day Avg. Volume1,003,339
Standard Deviation0.38
R-Squared0.19
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)16.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-10.08
Forecast
1Y Price Target
$64.45Price Target Upside25.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Biohaven Ltd. News
Bulls Say, Bears Say
Bulls Say
Competitive DifferentiationAn advantage for taldefgrobep is that it is administered subcutaneously at-home and would launch with an autoinjector, in contrast to the IV administration of apitegromab.
Market OpportunitiesThe positive Phase 3 SAPPHIRE data of Scholar Rock's apitegromab in spinal muscular atrophy bodes well for the upcoming readout of Biohaven's Phase 3 RESILIENT trial of taldefgrobep alfa.
Pipeline AdvancementsPositive readthrough to Biohaven's taldefgrobep alfa is suggested due to the similar study design and expected outcomes in SMA treatments.
Bears Say
Clinical Trial ChallengesTroriluzole has a checkered history as the drug previously failed in a Ph2/3 SCA study in 2017, failed in a Ph3 trial in generalized anxiety disorder (GAD), failed in a Ph2/3 study in obsessive compulsive disorder (OCD), and failed in a Phase 2/3 study in Alzheimer's disease.
Financial PerformanceThe company has high cash burn and there is some risk in near-term read-out, such as the SMA trial potentially missing its targets.
Regulatory IssuesThis opportunity carries a significant regulatory risk given the lack of robust placebo-controlled evidence, as the product failed in a Phase 2/3 trial and a Phase 3 trial, and the company received a refuse to file letter previously for its NDA filing based on subgroup analysis.
---
Ownership Overview
14.61% Insiders
20.67% Mutual Funds
1.18% Other Institutional Investors
50.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $25.97 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Currently, no data Available
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Nov 06, 2024 which is in 15 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Aug 08, 2024. The company reported -$3.64 earnings per share for the quarter, missing the consensus estimate of -$1.781 by -$1.859.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -$1.7.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 100,951,820 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$3.64 in its last earnings report, missing expectations of -$1.781. Following the earnings report the stock price went up 6.253%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Among the largest hedge funds holding Biohaven Ltd.’s share is Farallon Capital Management, L.L.C.. It holds Biohaven Ltd.’s shares valued at 78M.
---
Biohaven Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.45 (25.54% Upside)
$64.45 (25.54% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.51%
12-Months-Change
Fundamentals
Return on Equity
-193.67%
Trailing 12-Months
Asset Growth
14.98%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Month Forecast
Average Price Target
$64.45
▲(25.54% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+64.49%
reiterated a buy rating 29 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +64.49% per trade.
---